Discounted for a Reason: Abivax’s Losses Eclipse Growth
Abivax is cheap, but the losses are overwhelming. The market prices survival, not growth, with an operating margin of -4183.7%. This is a biotech bet on clinical milestones. Growth means little when the red ink runs this deep.
Published by AssetNext · 2026-06-06
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-07-03 | Weak profile, strong price | 40 | 0.0% | +58.9% |
| 2026-07-01 | Weak profile, strong price | 40 | -4.0% | +82.1% |
| 2026-06-26 | Profile and price weak | 40 | -31.0% | -25.8% |
Break down ABVX.PA's structural position across all peer dimensions with the interactive app.